Tag: 200-300

Stabilization of i-motif structures by 2′-β-fluorination of DNA was written by Abou Assi, Hala; Harkness, Robert W.; Martin-Pintado, V. Nerea; Wilds, Christopher J.; Campos-Olivas, Ramon; Mittermaier, Anthony K.; Gonzalez, Carlos; Damha, Masad J.. And the article was included in Nucleic Acids Research on June 20,2016.Category: pyrimidines The following contents are mentioned in the article:

I-Motifs are four-stranded DNA structures consisting of two parallel DNA duplexes held together by hemi-protonated and intercalated cytosine base pairs (C:CH+). They have attracted considerable research interest for their potential role in gene regulation and their use as pH responsive switches and building blocks in macromol. assemblies. At neutral and basic pH values, the cytosine bases deprotonate and the structure unfolds into single strands. To avoid this limitation and expand the range of environmental conditions supporting i-motif folding, we replaced the sugar in DNA by 2-deoxy-2- fluoroarabinose. We demonstrate that such a modification significantly stabilizes i-motif formation over a wide pH range, including pH 7. NMR experiments reveal that 2-deoxy-2- fluoroarabinose adopts a C2′-endo conformation, instead of the C3′-endo conformation usually found in unmodified i-motifs. Nevertheless, this substitution does not alter the overall i-motif structure. This conformational change, together with the changes in charge distribution in the sugar caused by the electroneg. fluorine atoms, leads to a number of favorable sequential and inter-strand electrostatic interactions. The availability of folded i-motifs at neutral pH will aid investigations into the biol. function of i-motifs in vitro, and will expand i-motif applications in nanotechnol. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Category: pyrimidines).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Category: pyrimidines

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Activity of 1-(2′-fluoro-2′-deoxy-β-D-arabinofuranosyl)thymine against herpes simplex virus in cell cultures and rabbit eyes was written by Trousdale, Melvin D.; Nesburn, Anthony B.; Su, Tsann Long; Lopez, Carlos; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Antimicrobial Agents and Chemotherapy on June 30,1983.Related Products of 69256-17-3 The following contents are mentioned in the article:

A new antiviral compound 1-(2′-fluoro-2′-deoxy-β-D-arabinofuranosyl)thymine (FMAU)(I) [69256-17-3], was compared with acyclovir and idoxuridine in vitro against 2 strains of both herpes simplex virus type 1 (HSV-1) and HSV-2. Determinations of the 50% ED varied slightly with each strain and with the host cells employed. The 50% ED for FMAU and acyclovir against HSV-1 ranged from 0.1 μM to 0.5 to 0.6 μM in rabbit kidney cells and from 0.5 μM to 0.6 to 0.78 μM in Vero cells. Beginning 4 days post-inoculation, topical FMAU therapy given 5 times per day to rabbits with acute herpetic keratitis either suppressed or delayed the severity of corneal epithelial involvement, conjunctivitis, iritis, and corneal clouding. Responses to treatment with FMAU were similar to those obtained with acyclovir and significantly better than those attained with idoxuridine and vidarabine. At 30 to 40 days after the end of treatment, rabbit eyes were subjected to iontophoresis with epinephrine in an attempt to induce reactivation and enhance detection of previously latent HSV-1. Latent HSV-1 was detected in 67 to 92% of trigeminal ganglia in FMAU-treated animals and in 90% of placebo-treated animals. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Related Products of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Related Products of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Evaluation of 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo was written by Alauddin, Mian M.; Shahinian, Atranik; Gordon, Erlinda M.; Conti, Peter S.. And the article was included in Molecular Imaging on June 30,2002.Reference of 69256-17-3 The following contents are mentioned in the article:

2′-Deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) has been evaluated in HT-29 cells as a potential positron emission tomog. (PET) radiotracer for imaging HSV-tk gene expression in vivo. In vitro experiments demonstrate that the accumulation of [14C]-FMAU in HSV-tk-expressing cells is 2.4-fold (p < .02), 4.0-fold (p < .001), and 5.3-fold (p < .001) higher than the wild-type cells at 1, 3, and 5 h, resp. In vivo studies revealed that the tumor uptake in HSV-tk-expressing cells was 2.3-fold (p < .001), 3.0-fold (p < .001), and 5.5-fold (p < .001) higher than the control cells at 1, 2, and 5 h, resp. FMAU was found to be more sensitive compared to our earlier studies using 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]-guanine ([18F]-FHPG) and 9-(4-[18F]-fluoro-3-hydroxy-methylbutyl)guanine ([18F]-FHBG) in the same cell lines, although, the specificity was less than FHBG. These results suggest that while FMAU labeled with PET isotopes may be useful for imaging HSV-tk-expressing tumors in vivo, multitracer studies across addnl. tumor models are necessary in order to identify an optimal PET radiotracer. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Reference of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Reference of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Efficient and Accurate Potential Energy Surfaces of Puckering in Sugar-Modified Nucleosides was written by Mattelaer, Charles-Alexandre; Mattelaer, Henri-Philippe; Rihon, Jerome; Froeyen, Matheus; Lescrinier, Eveline. And the article was included in Journal of Chemical Theory and Computation on June 8,2021.Category: pyrimidines The following contents are mentioned in the article:

Puckering of the sugar unit in nucleosides and nucleotides is an important structural aspect that directly influences the helical structure of nucleic acids. The preference for specific puckering modes in nucleic acids can be analyzed via in silico conformational anal., but the large amount of conformations and the accuracy of the anal. leads to an extensive amount of computational time. In this paper, we show that the combination of geometry optimizations with the HF-3c method with single point energies at the RI-MP2 level results in accurate results for the puckering potential energy surface (PES) of DNA and RNA nucleosides while significantly reducing the necessary computational time. Applying this method to a series of known xeno nucleic acids (XNAs) allowed us to rapidly explore the puckering PES of each of the resp. nucleosides and to explore the puckering PES of six-membered modified XNA (HNA and β-homo-DNA) for the first time. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Category: pyrimidines).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. For example, the neurotoxin tetrodotoxin is a pyrimidine derivative. It is found in a number of species including the Japanese puffer fish, the blue-ringed octopus, and the orange-bellied newt. Tetrodotoxin prevents the transmission of nerve signals and can result in paralysis and death.Category: pyrimidines

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus was written by Lin, Jung Chung; Smith, M. Carolyn; Pagano, Joseph S.. And the article was included in Antimicrobial Agents and Chemotherapy on June 30,1985.Product Details of 69256-17-3 The following contents are mentioned in the article:

The effects of (2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) [69123-90-6], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluridine (FMAU) [69256-17-3], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouridine (FIAU) [69123-98-4], (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVdU) [69304-47-8], and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG or BW B759U) [82410-32-0] on the replication of Epstein-Barr virus (EBV) in vitro were evaluated and compared with that of acyclovir (ACV). The relative potencies of these drugs, on the basis of anti-EBV activity, were: FIAC = FIAU > FMAU > DHPG > BVdU > ACV; on the basis of the therapeutic index they were: BVdU > DHPG > FIAC > ACV > FIAU > FMAU. Differential inhibition of EBV-associated polypeptides by these drugs was observed This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Product Details of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine nitrogenous bases are derived from the organic compound pyrimidine through the addition of various functional groups. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Product Details of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

In vitro and in vivo antiviral activity of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds was written by Machida, Haruhiko; Sakata, Shinji. And the article was included in Antiviral Research on June 30,1984.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

BV-araU (I) [77181-69-2] and related compounds such as CV-araU [77181-70-5], IV-araU [87535-95-3], and BV-araUMP [86230-31-1] showed marked activity against herpes simplex virus type 1 (HSV-1) in human embryonic lung fibroblast cells. BV-araU, CB-araU, and BV-araUMP were also effective in mice infected intracerebrally with HSV-1. Especially, when mice were infected with a low dose of virus, both i.v. and oral treatment with BV-araU proved capable of increasing the mean survival time and decreasing the final mortality of the infected mice. The in vivo anti-HSV-1 activity of BV-araU was comparable to that of E-5-(2-bromovinyl)-2′-deoxyuridine  [69304-47-8]. BV-araU exhibited little toxicity for mice. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine was written by Philips, Frederick S.; Feinberg, Aaron; Chou, Ting Chao; Vidal, Pedro M.; Su, Tsann Long; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Cancer Research on August 31,1983.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

The pharmacologicl disposition and metabolic fate of 2-14C-labeled 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine (FMAU)(I) [69256-17-3] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC)(II) [69123-90-6] were compared after giving each of the substances i.v. or orally. Most of the radioactivity of these substances is excreted in urine within 24 h after administration in mice and rats. During the same period, the recovery in feces and respiratory CO2 is, for each, < 5%. Biliary excretion from the common bile duct of rats is low, 2 to 4% of dose during the first 5 h after i.v. injection. Chromatog. anal. of 24-h urine collections after giving FMAU reveals that most of the radioactivity in mouse and rat urine is present as unchanged drug. Mouse urine also contains significant amounts of 3 unidentified metabolites of FMAU; these have also been detected in mouse plasma and in rat urine. Chromatog. analyses of plasma and urine samples from mice and rats given FIAC show that this substance is substantially transformed by deamination into a major metabolite, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-ioduracil  [69123-98-4]. Deiodinated metabolites have also been detected, namely, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine  [56632-83-8] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil  [69123-94-0]. Radioactivity in extracerebral organs of rats receiving labeled FIAC or FMAU is, within 10 min after i.v. injection, maximal and in concentrations equivalent to or higher than in plasma. Maximal concentrations after oral doses are reached within 30 to 60 min. At later times, rates of decrease in extracerebral organs parallel those in plasma. Half-lives after oral doses are higher than after i.v. doses. Penetration of radioactivity into rat brain is rapid, and the ratio of brain to plasma concentrations increases steadily to over 0.5 during the first 6 h after dosing. Substantially greater concentrations appear in brain after FMAU than after FIAC. Studies of radioactivity remaining in various portions of the gut of rats given oral doses of the labeled drugs suggest that most of the absorption takes place from the stomach or upper end of the small intestine. In dogs, the rates of renal clearance of FMAU and FIAC are less than 20% that of creatine when plasma concentrations are 10-fold greater than that inhibiting herpes virus replication in vitro by 90%. Nearly all of the radioactivity excreted in dog urine during the first 24 h after i.v. [2-14C]FMAU consists of unchanged drug. After [2-14C]FIAC, the 24-h urinary radioactivity is composed primarily of unchanged drug and the deiodinated metabolites, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil; only trace amounts of the deaminated product, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil, were detected. The synthesis of [2-14C]FMAU [83374-60-1] is described. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine was written by Philips, Frederick S.; Feinberg, Aaron; Chou, Ting Chao; Vidal, Pedro M.; Su, Tsann Long; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Cancer Research on August 31,1983.HPLC of Formula: 56632-83-8 The following contents are mentioned in the article:

The pharmacologicl disposition and metabolic fate of 2-14C-labeled 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine (FMAU)(I) [69256-17-3] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC)(II) [69123-90-6] were compared after giving each of the substances i.v. or orally. Most of the radioactivity of these substances is excreted in urine within 24 h after administration in mice and rats. During the same period, the recovery in feces and respiratory CO2 is, for each, < 5%. Biliary excretion from the common bile duct of rats is low, 2 to 4% of dose during the first 5 h after i.v. injection. Chromatog. anal. of 24-h urine collections after giving FMAU reveals that most of the radioactivity in mouse and rat urine is present as unchanged drug. Mouse urine also contains significant amounts of 3 unidentified metabolites of FMAU; these have also been detected in mouse plasma and in rat urine. Chromatog. analyses of plasma and urine samples from mice and rats given FIAC show that this substance is substantially transformed by deamination into a major metabolite, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-ioduracil  [69123-98-4]. Deiodinated metabolites have also been detected, namely, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine  [56632-83-8] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil  [69123-94-0]. Radioactivity in extracerebral organs of rats receiving labeled FIAC or FMAU is, within 10 min after i.v. injection, maximal and in concentrations equivalent to or higher than in plasma. Maximal concentrations after oral doses are reached within 30 to 60 min. At later times, rates of decrease in extracerebral organs parallel those in plasma. Half-lives after oral doses are higher than after i.v. doses. Penetration of radioactivity into rat brain is rapid, and the ratio of brain to plasma concentrations increases steadily to over 0.5 during the first 6 h after dosing. Substantially greater concentrations appear in brain after FMAU than after FIAC. Studies of radioactivity remaining in various portions of the gut of rats given oral doses of the labeled drugs suggest that most of the absorption takes place from the stomach or upper end of the small intestine. In dogs, the rates of renal clearance of FMAU and FIAC are less than 20% that of creatine when plasma concentrations are 10-fold greater than that inhibiting herpes virus replication in vitro by 90%. Nearly all of the radioactivity excreted in dog urine during the first 24 h after i.v. [2-14C]FMAU consists of unchanged drug. After [2-14C]FIAC, the 24-h urinary radioactivity is composed primarily of unchanged drug and the deiodinated metabolites, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil; only trace amounts of the deaminated product, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil, were detected. The synthesis of [2-14C]FMAU [83374-60-1] is described. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8HPLC of Formula: 56632-83-8).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.HPLC of Formula: 56632-83-8

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing was written by Fourel, Isabelle; Gripon, Philippe; Hantz, Oliver; Cova, Lucyna; Lambert, Veronique; Jacquet, Chantal; Watanabe, Kyoichi; Fox, Jack; Guillouzo, Christiane; Trepo, Christian. And the article was included in Hepatology (Philadelphia, PA, United States) on August 31,1989.HPLC of Formula: 69256-17-3 The following contents are mentioned in the article:

Duck cultured hepatocytes from Pekin ducks naturally infected by duck hepatitis B virus can remain functional twice longer if a coculture system with rat liver epithelial cells is used instead of ordinary primary culture. The use of a selective medium in which ornithine and lactate replaced arginine and glucose, resp., allowed viral replication initiated in vivo to be maintained in the coculture for 2 mo. Several antiviral compounds including the pyrophosphate analog (phosphonoformic acid) or nucleoside analogs (9β-arabinofuranosyl AMP, 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-iodocytosine, 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil and 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl thymine) were studied in both culture systems for their ability to inhibit duck hepatitis B virus replication. Hepatocytes were treated for 7 days with 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil (10 μM) and 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosylthymine (0.5 μM) or for 14 days with 9β-arabinofuranosyl AMP (90 μM), phosphonoformic acid (100 μM) and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (6 μM). The effects of the drugs on viral replication were monitored by testing for duck hepatitis B virus DNA in the culture supernatant and in the cells by mol. hybridization. All the above-mentioned drugs demonstrated an inhibitory activity in both types of cultures which at the quite distinct doses used was greater for phosphonoformic acid and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine than for 9β-arabinofuranosyl AMP, 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil or 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl thymine. Viral replication, however, resumed following discontinuation of treatment. More studies are needed to further confirm the relevance of this tissue culture system for the screening of new potential anti-hepatitis B virus agents. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3HPLC of Formula: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.HPLC of Formula: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2 was written by Tehrani, Omid S.; Douglas, Kirk A.; Lawhorn-Crews, Jawana M.; Shields, Anthony F.. And the article was included in European Journal of Nuclear Medicine and Molecular Imaging on August 31,2008.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Fluoropyrimidines like 1-(2′-deoxy-2′-fluoro-β-d-arabinofuranosyl)-thymine (FMAU) and 3′-deoxy-3′-fluorothymidine (FLT) accumulate in tumors and are being used as positron emission tomog. tumor-imaging tracers. Proliferating tissues with high thymidine kinase 1 (TK1) activity retain FLT; however, the mechanism of selective accumulation of FMAU in tumors and certain other tissues requires further study. Retention of [3H]FLT and [3H]FMAU was measured in prostate cancer cell lines PC3, LNCaP, DU145, and the breast cancer cell line MD-MBA-231, and the tracer metabolites were analyzed by high-performance liquid chromatog. (HPLC). FMAU retention, thymidine kinase 2 (TK2) activity, and mitochondrial mass were determined in cells stressed by depleted cell culture medium or by treating with oxidative, reductive, and energy stress, or specific adenosine monophosphate-activated protein kinase activator, or eIF2 inhibitor. TK1 and TK2 activities and mitochondrial mass were determined by FLT phosphorylation, 1-β-d-arabinofuranosylthymine (Ara-T) phosphorylation, and flow cytometry, resp. FMAU retention in rapidly proliferating cancer cell lines was five to ten times lower than FLT after 10 min incubation. HPLC anal. of the cellular extracts showed that phosphorylated tracers are the main retained metabolites. Nutritional stress decreased TK1 activity and FLT retention but increased retained FMAU. TK2 inhibition decreased FMAU retention and phosphorylation with negligible effects on FLT. Oxidative, reductive, or energy stress increased FMAU retention and correlated with mitochondrial mass (r2 = 0.88, p = 0.006). FMAU phosphorylation correlated with increased TK2 activity (r2 = 0.87, p = 0.0002). FMAU is preferably phosphorylated by TK2 and can track TK2 activity and mitochondrial mass in cellular stress. FMAU may provide an early marker of treatment effects. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3